Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

"We sought to identify alternative ways to inhibit TGFβ signaling using human hepatic stellate cells and macrophages from ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

A family from Co Armagh have launched a fundraiser to help install a fundraiser for their dad who was diagnosed with ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

COVID-19 has no impact on body mass index (BMI) trajectory or lung function in people with cystic fibrosis (pwCF) in the year following infection.

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The presentation will also be available on the 4DMT website: #posters-and-publications ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...